Abstract |
This trial was initiated to evaluate the toxicity and activity of combination chemotherapy employing cisplatin (CDDP), docetaxel (DCT) and ifosfamide (IFX) in non-small cell lung cancer (NSCLC), and to determine the maximum tolerated dose (MTD) of IFX. Chemotherapy-naive patients with advanced or recurrent NSCLC received 60 mg/m(2) DCT followed after a 3-h interval by 60 mg/m(2) CDDP on chemotherapy day 1, and IFX at an escalating dose with mesna protection on days 2-4. The chemotherapy was repeated every 3 weeks. Granulocyte colony-stimulating factor (GCSF) was administered in the event of grade 3 leukopenia/ neutropenia. The patients tolerated the treatment well up to level 4 of IFX dosing 1.5 g/day, but not the IFX dose at level 6 (2.0 g/day). Additional patients were enrolled in level 5 (IFX 1.7 g/day) to evaluate the toxicity of the drugs around the MTD. Level 5 was also judged as having exceeded the MTD, with febrile neutropenia and hepatic toxicity being observed as the dose-limiting toxicities. No toxicity-related deaths occurred. The majority of the chemotherapy courses were supported by GCSF administration. A total of 33 eligible patients were entered into the trial; the overall response rate was 10/33 or 30% among all eligible cases, and the rate for patients treated with the MTD or higher (levels 4-6) was 8/24, or 33% (90% confidence limit: 18-52%). The MTD of IFX was 1.5 g/m(2) administered for 3 days in this triplet combination. The clinical activity does not seem to justify the toxicity profile.
|
Authors | H Kunitoh, Y Akiyama, H Kusaba, N Yamamoto, I Sekine, Y Ohe, K Kubota, T Tamura, T Shinkai, T Kodama, K Goto, S Niho, Y Nishiwaki, N Saijo |
Journal | Lung cancer (Amsterdam, Netherlands)
(Lung Cancer)
2001 Aug-Sep
Vol. 33
Issue 2-3
Pg. 259-65
ISSN: 0169-5002 [Print] Ireland |
PMID | 11551421
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Taxoids
- Docetaxel
- Paclitaxel
- Cisplatin
- Ifosfamide
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Cisplatin
(administration & dosage)
- Docetaxel
- Dose-Response Relationship, Drug
- Female
- Humans
- Ifosfamide
(administration & dosage)
- Infusions, Intravenous
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Recurrence, Local
- Paclitaxel
(administration & dosage, analogs & derivatives)
- Taxoids
|